Aarti Pharmalabs Limited
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals
What Aarti files
- Others55
- Investor Meet29
- Updates11
- Important10
- Board Meeting10
- Dividend/Bonus9
Aarti Pharmalabs received an order for a Rs. 59.50 Cr stamp duty and penalty related to its demerger scheme. The company will challenge this, believing it has a strong legal case.
Aarti Pharmalabs inaugurated a new manufacturing block at Tarapur, adding 3600 TPA to Xanthine derivatives capacity, now totaling 9600 TPA. This positions them among the top 3 global manufacturers. Trial production has begun, with full utilization expected in coming quarters.
AARTI PHARMALABS' board approved audited financial results for the quarter and financial year. Consolidated Net Profit was Rs 61.12 Cr (Q4) and Rs 174.71 Cr (FY). A final dividend of Rs 2/- per share was declared.
Aarti Pharmalabs clarified a prior disclosure delay. A key official was on leave, causing a relevant email to be missed and resulting in a late filing.
Aarti Pharmalabs received a Rs. 0.026 Cr penalty from tax authorities for alleged GST compliance issues in FY22-23 and FY23-24. The company anticipates no material financial or operational impact from this action.